The abstract is read at the publisher; the summary is JClub's.
Up to 95% of MASLD cases in people with type 2 diabetes remain undiagnosed due to lack of accepted steatosis assessment recommendations, while non-invasive tests overestimate progression.
- Why it matters: The liver is closely linked to metabolic dysfunction in type 2 diabetes, yet MASLD and fibrosis are not consistently recognized or managed, limiting timely diagnosis and care.
- What they did: This Diabetologia special issue reviews diagnosis and management challenges for MASLD and fibrosis in type 2 diabetes, highlighting predictors like metabolic syndrome features and genetic subtypes such as PNPLA3 I148M.
- The result: New therapies targeting hepatic energy metabolism or weight loss are promising for fibrosis remission, but improving MASH diagnostic rates will require clinician awareness and expanded community-based testing with cost-effectiveness analyses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.